Morphosys Ag

Novartis Ag

Steffen Runz

Julia Neugebauer

Stefanie Urlinger

Thomas Tiller

John Trauger

Andreas Bültmann

Andrei Igorevich Voznesensky

Kerstin Uhland

The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.

Antibodies targeting Glycoprotein VI

The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.

Humanized antibodies for CD3

The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region. The modified constant region prevents the recognition of the Fab molecules by anti-Fab antibodies present in a host's serum. The disclosure further relates to methods of generating such modified Fab molecules for biological, diagnostic, pharmaceutical and other uses.

Fab molecules with a rodent hinge region and a non-rodent CH1 region

The present invention relates to monoclonal antibodies binding to human angiopoetin-like protein 4 (hereinafter, sometimes referred to as 'ANGPTL4'), and pharmaceutical compositions and methods of treatment comprising the same.

Growing community of inventors

Munich, Germany

Steffen Runz